Compare NEON & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NEON | JSPR |
|---|---|---|
| Founded | 1997 | 2018 |
| Country | Sweden | United States |
| Employees | N/A | 22 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.9M | 23.1M |
| IPO Year | 1994 | N/A |
| Metric | NEON | JSPR |
|---|---|---|
| Price | $1.70 | $0.95 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $6.00 | ★ $15.50 |
| AVG Volume (30 Days) | 84.5K | ★ 567.1K |
| Earning Date | 05-13-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 37.88 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,108,000.00 | N/A |
| Revenue This Year | $72.74 | N/A |
| Revenue Next Year | $28.94 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.27 | $0.62 |
| 52 Week High | $29.90 | $7.19 |
| Indicator | NEON | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 60.66 | 47.89 |
| Support Level | $1.69 | $0.81 |
| Resistance Level | $1.74 | $1.12 |
| Average True Range (ATR) | 0.10 | 0.10 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 88.57 | 42.03 |
Neonode Inc provides optical sensing solutions for contactless touch, and gesture sensing and also provides software solutions for machine perception that feature machine learning algorithms to detect and track persons and objects in video streams from cameras and other types of imagers. It markets and sells its solutions to customers in many different markets and segments including, office equipment, automotive, industrial automation, medical, military, and avionics. The company geographically operates in the United States, Japan, South Korea, Germany, Sweden, China, and other regions. A majority of its revenue is generated from Japan.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.